1921
Volume 84, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Chagas cardiomyopathy remodeling is based on the presence of in heart tissue and on the complex inflammatory response leading to a myocardium fibrosis and alterations in conductive and functional heart parameters. This study aims to evaluate Simvastatin on the inflammatory response and heart functionality using dogs infected with Y strain of . Animals were treated daily with Simvastatin (20 mg) for 6 months and submitted to clinical and immunopathological evaluations. Simvastatin reduced heart expression and serum levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) but not interleukin-10 (IL-10), possibly favoring blood parasitism but reducing inflammation and fibrosis in the left ventricle and right atrium. Simvastatin also ameliorated ejection fraction, diastolic diameter, and mass index of the left ventricle 6 months after infection. This study suggests that more investigation should be performed on the use of statins as a prophylactic therapy against cardiac remodeling because of their effects on modifying immune response and benefiting functional parameters in dogs with -induced ventricular dysfunctions.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2011.10-0451
2011-02-04
2017-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/84/2/325.html?itemId=/content/journals/10.4269/ajtmh.2011.10-0451&mimeType=html&fmt=ahah

References

  1. Pan American Health Organization (PAHO)–World Health Organization (WHO), 2006. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: Organizacion Panamericana de la Salud; CD/425-06.
  2. Feldman AM, McNemara D, , 2000. Myocarditis. N Engl J Med 343: 13881398.[Crossref]
  3. Rocha MO, Teixeira MM, Ribeiro AL, , 2007. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5: 727743.[Crossref]
  4. Dutra WO, Rocha MO, Teixeira MM, , 2005. The clinical immunology of human Chagas disease. Trends Parasitol 21: 581587.[Crossref]
  5. Gutierrez FR, Guedes PM, Gazzinelli RT, Silva JS, , 2009. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol 31: 673685.[Crossref]
  6. Abrahamsohn IA, Coffman RL, , 1996. Trypanosoma cruzi: IL-10, TNF, IFN-gamma and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol 84: 231244.[Crossref]
  7. Brener Z, Gazzinelli RT, , 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas disease. Int Arch Allergy Immunol 114: 103110.[Crossref]
  8. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, Murta SM, Romanha AJ, Almeida IC, Farber J, Lannes-Vieira J, Silva JS, Gazzinelli RT, , 2000. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi . Microbes Infect 2: 851866.[Crossref]
  9. Urbina JA, , 2009. New advances in the management of a long-neglected disease. Clin Infect Dis 49: 16851687.[Crossref]
  10. Node K, Fujita M, Kitakaze M, Hori M, Liao JK, , 2003. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839843.[Crossref]
  11. Shanes JG, Minadeo KN, Moret A, Groner M, Tabaic SA, , 2007. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J 154: 617623.[Crossref]
  12. Weis M, Heeschen C, Glassford AJ, Cooke JP, , 2002. Statins have biphasic effects on angiogenesis. Circulation 105: 739745.[Crossref]
  13. Cheng X, Liao YH, Zhang J, Li B, Ge H, Yuan J, Wang M, Lu B, Liu Y, Cheng Y, , 2005. Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction. Eur J Heart Fail 7: 10991104.[Crossref]
  14. Robinson JG, , 2008. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects and cardiovascular risk. Am J Cardiol 101: 10091015.[Crossref]
  15. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, , 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291: 10711080.[Crossref]
  16. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM, , 2006. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47: 25542560.[Crossref]
  17. Guedes PM, Veloso VM, Afonso LC, Caliari MV, Carneiro CM, Diniz LF, Marques-da-Silva EA, Caldas IS, Do Valle Matta MA, Souza SM, Lana M, Chiari E, Galvão LM, Bahia MT, , 2009. Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase. Vet Immunol Immunopathol 130: 4352.[Crossref]
  18. Guedes PM, Veloso VM, Talvani A, Diniz LF, Caldas IS, Do-Valle-Matta MA, Santiago-Silva J, Chiari E, Galvão LM, Silva JS, Bahia MT, , 2010. Increased type 1 chemokine expression in experimental Chagas disease correlates with cardiac pathology in Beagle dogs. Vet Immunol Immunopathol 138: 106113.[Crossref]
  19. Zaca V, Rastogi S, Imai M, Wang M, Sharov VG, Jiang A, Goldstein S, Sabbah HN, , 2007. Chronic monotherapy with Rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50: 551557.[Crossref]
  20. Shiroshita-Takeshita A, Brundel BJJM, Burstein B, Leung TK, Mitamura H, Ogawa S, Nattel S, , 2007. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 74: 7584.[Crossref]
  21. Pedersen TR, Tobert JA, , 2004. Simvastatin: a review. Expert Opin Pharmacother 5: 25832596.[Crossref]
  22. Morris SA, Tanowitz HB, Wittner M, Bilezikian JP, , 1990. Pathophysiological insights into the cardiomyopathy of Chagas disease. Circulation 82: 19001909.[Crossref]
  23. Botoni FA, Poole-Wilson PA, Ribeiro AL, Okonko DO, Oliveira BM, Pinto AS, Teixeira MM, Teixeira AL, Jr Reis AM, Dantas JB, Ferreira CS, Tavares WC, Jr Rocha MO, , 2007. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 153: 544e1544e8.[Crossref]
  24. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, , 2007. Treating patients with Chagas cardiomyopathy with chronic heart failure in the contemporary era. Am Heart J 154: 35e.[Crossref]
  25. Issa VS, Amaral AF, Cruz FD, Ferreira SM, Guimarães GV, Chizzola PR, Souza GE, Bacal F, Bocchi EA, , 2010. Beta-Blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective Trial. Circ Heart Fail 3: 8288.[Crossref]
  26. Paula-Costa G GP, Silva RR, Pedrosa MC, Pinho V, Lima WG, Teixeira MM, Bahia MT, Talvani A, , 2010. Enalapril prevents cardiac immune-mediated damage and exerts anti-Trypanosoma cruzi activity during acute phase of experimental Chagas disease. Parasite Immunol 32: 202208.[Crossref]
  27. Goldstein JL, Brown MS, , 1990. Regulation of the mevalonate pathway. Nature 343: 425430.[Crossref]
  28. Concepcion JL, Gonzalez-Pacanowska D, Urbina JA, , 1998. 3-Hydroxy-3-methyl-glutaryl-CoA reductase in Trypanosoma (Schizotrypanum) cruzi: subcellular localization and kinetic properties. Arch Biochem Biophys 352: 114120.[Crossref]
  29. Silva JS, Machado FS, Martins GA, , 2003. The role of nitric oxide in the pathogenesis of Chagas disease. Front Biosci 1: 314325.[Crossref]
  30. Cummings KL, Tarleton RL, , 2004. Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun 72: 40814089.[Crossref]
  31. Coelho PS, Klein A, Talvani A, Coutinho SF, Takeuchi O, Akira S, Silva JS, Canizzaro H, Gazzinelli RT, Teixeira MM, , 2002. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes induce in vivo leukocyte recruitment dependent on MCP-1 production by IFN-gamma-primed-macrophages. J Leukoc Biol 71: 837844.
  32. Gomes JA, Bahia-Oliveira LM, Rocha MO, Martins-Filho OA, Gazzinelli G, Correa-Oliveira R, , 2003. Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun 71: 11851193.[Crossref]
  33. Cunha-Neto E, Nogueira LG, Teixeira PC, Ramasawmy R, Drigo SA, Goldberg AC, Fonseca SG, Bilate AM, Kalil J, , 2009. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz 104 (Suppl 1): 252258.[Crossref]
  34. de Lana M, Chiari E, Tafuri WL, , 1992. Experimental Chagas' disease in dogs. Mem Inst Oswaldo Cruz 87: 5971.[Crossref]
  35. Gunja-Smith Z, Morales AR, Romanelli R, Woessner FR, Jr, 1996. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline crosslinks. Am J Pathol 1448: 16391648.
  36. Chou DH, Lee W, McCulloch CA, , 1996. TNF-alpha inactivation of collagen receptors: implications for fibroblasts function and fibrosis. J Immunol 156: 43544362.
  37. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH, , 1999. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res 85: 272279.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.10-0451
Loading
/content/journals/10.4269/ajtmh.2011.10-0451
Loading

Data & Media loading...

  • Received : 12 Aug 2010
  • Accepted : 01 Nov 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error